 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 5,883,669 shares were traded during mid-day trading, an increase of 210% from the...

Mesoblast (NASDAQ:MESO) Sees Strong Trading Volume

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price was up 6.6% on Tuesday . The company traded as high as $6.48 and last traded at $6.48. Approximately 1,516,520 shares changed hands...

Mesoblast (NASDAQ:MESO) Trading Up 6.6%

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $3.49, but opened at $4.46. Mesoblast shares last traded at...

Mesoblast (NASDAQ:MESO) Shares Gap Up to $3.49

In this piece, we will take a look at the ten best long term ASX stocks to invest in. If you want to skip our overview of the Australian stock market, then you can take a look at the 5 Best Long Term...

10 Best Long Term ASX Stocks To Invest In

iBio, Mesoblast, Kodiak Sciences among healthcare movers...

iBio, Mesoblast, Kodiak Sciences among healthcare movers

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mesoblast reports FDA notification that MSB-GVHD001 data appears sufficient

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has...

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm...

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA...

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

StockNews.com upgraded shares of Mesoblast (NASDAQ:MESO  Free Report) from a sell rating to a hold rating in a research report report published on Monday morning. Separately, Cantor Fitzgerald...

Mesoblast (NASDAQ:MESO) Raised to "Hold" at StockNews.com

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Volume (M)	134,426.00
52-Wk High	$10.24
52-Wk Low	$1.61

MESO Mesoblast limited.

About

Feed

News

Sentiment

Earnings

Fundamentals